Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer’s Hopes For Ibrance In Adjuvant Breast Cancer Fall With PALLAS

Executive Summary

Ibrance (palbociclib) is unlikely to succeed in the adjuvant trial, the data safety monitoring board concluded. Pfizer has another adjuvant trial due later this year. 

You may also be interested in...



Stockwatch: MonarchE And Tug-Of-War Drug Development

With Lilly, Pfizer and Novartis duking it out for early-stage breast cancer patients, how many drugs for the same indication is too many?

Next Generation SERDs Progress In Breast Cancer; Standing Out In The Crowd Won't Be Easy

The class is poised to be a competitive one with Sanofi, AstraZeneca, Roche and Zentalis among the contenders developing new selective estrogen receptor degraders for HER2-negative breast cancer.

Survival Data Boost Lilly & Novartis’s CDK4/6 Assault On Pfizer’s Ibrance In Metastatic Breast Cancer

Pfizer’s dominance of the CDK4/6 inhibitor market will come under renewed pressure as the MONALEESA-3 and MONARCH-2 studies for Novartis’s Kisqali and Lilly’s Verzenio presented at ESMO confirmed their survival benefits in advanced hormone-receptor-positive, HER2-negative breast cancer. The data firmly push the drug class into front-line advanced setting in these patients.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1131690

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel